Executive Summary

The August 26, 2026 approval of daraxonrasib for metastatic pancreatic adenocarcinoma marked a change in the treatment landscape. The oral RAS inhibitor demonstrated improvement in overall survival, progression free survival, and tumor response compared with chemotherapy in a randomized trial of patients whose cancer had progressed after an earlier systemic regimen.

The preceding three decades established a sequence of treatment advances. Gemcitabine provided an early chemotherapy foundation; combinations involving fluorouracil, oxaliplatin, irinotecan, and albumin bound paclitaxel subsequently expanded systemic therapy. A liposomal irinotecan regimen gained an additional first line indication in 2024.

Molecular testing also opened narrower therapeutic paths. Maintenance olaparib became available for selected patients with inherited BRCA mutations, while targeted agents and immunotherapies with biomarker defined or tumor agnostic indications reached subsets of pancreatic cancer patients. A pancreatic specific approval for NRG1 fusion positive disease arrived in 2024.

Daraxonrasib offers a new option after prior systemic treatment and for adults who cannot receive multiagent therapy. Its broad RAS activity and randomized survival evidence set it apart within the existing sequence, although adverse effects, patient selection, and further use in earlier treatment settings remain central clinical questions.

The Disease and Its Treatment Context

Pancreatic ductal adenocarcinoma (PDAC) accounts for most pancreatic cancer cases and often presents after curative surgery is no longer possible. The National Cancer Institute (NCI) describes treatment according to resectability, stage, prior therapies, and patient fitness. Systemic therapy is central to metastatic disease, while surgery and additional therapy may be appropriate in localized settings. 12

For a professional assessment of United States (US) approvals, it is useful to distinguish three regulatory pathways: drugs approved specifically for pancreatic cancer; drugs indicated for an actionable molecular subtype; and agents approved for certain biomarkers across solid tumors regardless of primary site. These categories have different label restrictions and levels of pancreatic specific evidence. 345

A separate distinction is treatment intent. Evidence supporting a regimen after surgical resection cannot be assumed to establish efficacy in metastatic disease, and results in patients fit for intensive combinations cannot be transferred directly to those with limited functional reserve. The approved daraxonrasib population is defined by prior treatment or inability to receive multiagent systemic therapy. 16

Three Decades of FDA Approvals

The US Food and Drug Administration (FDA) approvals that shaped pancreatic adenocarcinoma treatment span cytotoxic drugs, biomarker selected maintenance therapy, antibody treatment for rare fusions, and RAS inhibition. Approval of a drug for another malignancy does not automatically create a pancreatic cancer indication; tumor agnostic labels are discussed separately below. 346

This timeline is selective. It emphasizes product approvals and material label changes affecting pancreatic adenocarcinoma, rather than every component of established combination chemotherapy. Several important regimens are assembled from individually approved medicines and are supported by clinical guidelines and trial evidence. 13

How Chemotherapy Changed Survival

Gemcitabine provided a reference regimen for advanced pancreatic cancer, and subsequent trials evaluated whether combinations improved survival. The clinical development of fluorouracil based combinations, gemcitabine plus albumin bound paclitaxel, and liposomal irinotecan regimens created treatment choices that vary by disease setting and patient fitness. 178

FOLFIRINOX combines folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin. It is an established regimen for appropriately selected patients with advanced disease and also has a role after resection in modified form. The regimen name denotes a combination rather than a single FDA approved branded product. 1

The choice among these regimens considers earlier drug exposure, expected adverse effects, functional status, neuropathy, marrow reserve, and patient preferences. Cross trial comparisons cannot establish a treatment hierarchy when populations, lines of therapy, and endpoints differ. 18

Treatment of Resectable and Locally Advanced Disease

In localized pancreatic cancer, treatment is shaped by whether the tumor can be removed surgically and whether major blood vessel involvement limits resection. Surgery remains a potentially curative approach for a selected group; chemotherapy before or after surgery may improve outcomes depending on the clinical setting. 1

Adjuvant modified FOLFIRINOX is a recognized option for medically fit patients after resection, alongside other chemotherapy approaches. For borderline resectable or locally advanced tumors, multidisciplinary evaluation can incorporate systemic therapy, reassessment of operability, and selected radiation approaches. These pathways are distinct from the metastatic indication approved for daraxonrasib in 2026. 16

In 2026 the FDA also approved Optune Pax, a medical device for a defined pancreatic cancer setting. Its authorization belongs to a device regulatory pathway and should be evaluated separately from drug approvals and the daraxonrasib trial. 910

The Emergence of Molecularly Targeted Treatment

The availability of therapies tied to molecular alterations increased the relevance of comprehensive tumor profiling and germline testing. Poly(ADP-ribose) polymerase (PARP) inhibition, DNA mismatch repair status, neurotrophic tyrosine receptor kinase (NTRK) fusions, BRAF variants, HER2 expression, RET fusions, and NRG1 rearrangements each have distinct regulatory conditions. A biomarker alone is insufficient when the corresponding label specifies disease setting, prior therapy, or additional criteria. 4115

Olaparib received a pancreatic specific maintenance indication for adults with metastatic disease and deleterious or suspected deleterious germline BRCA mutations whose disease had not progressed after at least 16 weeks of first line platinum chemotherapy. The POLO study established a progression free survival benefit, while its final overall survival analysis did not show a statistically significant difference. 1112

These biomarker defined indications do not guarantee that the underlying alteration is common in pancreatic cancer or that pancreas specific efficacy estimates are available. Clinical use requires confirming the current US prescribing information, an appropriate diagnostic result, and the precise indication. 4513

Daraxonrasib and the RAS Target

Daraxonrasib, previously identified as RMC-6236, is an oral inhibitor of the RAS family of guanosine triphosphatases (GTPases). RAS signaling promotes cellular proliferation; changes in this pathway are common in pancreatic ductal adenocarcinoma. The drug targets multiple RAS forms and is taken once daily. 214

On August 26, 2026, the FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma who had received at least one previous systemic treatment or who are not candidates for multiagent systemic therapy. The indication stated in the FDA notice does not require a specific RAS G12 mutation. The clinical trial nevertheless evaluated both the overall population and a prespecified RAS G12 mutation population. 6

The approved recommended dosage is 300 mg orally once daily, continued until disease progression or unacceptable toxicity. Treatment should follow the full prescribing information, including directions for management of toxicities and interactions. 615

Pancreatic Cancer: FDA Treatment Milestones and RASOLUTE 302

Click to enlarge

RASolute 302: The Evidence Supporting Approval

RASolute 302 (NCT06625320) was a randomized, open label, multicenter study involving 500 adults with metastatic pancreatic adenocarcinoma that progressed after one prior systemic treatment regimen. Participants were assigned equally to daraxonrasib or the physician's choice of standard chemotherapy. Major endpoints included overall survival (OS) and progression free survival (PFS); objective response rate (ORR) was an additional measure. 616

The FDA reported statistically significant improvements in survival, disease control, and response both among participants whose tumors had RAS G12 mutations and in the overall study population. The overall survival hazard ratio of 0.40 represents an estimated 60% reduction in the instantaneous risk of death over the observed period under the trial analysis, rather than a claim that 60% of patients were cured. 6

The numerical difference in median overall survival was 6.5 months between the trial groups. This is a within trial comparison in previously treated metastatic disease. Its interpretation should account for the enrolled population and the chemotherapy choices available to investigators. 616

Interpreting the Clinical Benefit

The primary strength of the daraxonrasib evidence is its randomized survival comparison against active chemotherapy, which directly addresses a consequential outcome in metastatic disease. Improvements in both overall and progression free survival, with a higher response rate, support the regulatory decision. 616

The study enrolled patients after progression on one systemic line, whereas the approved indication also includes adults deemed unsuitable for multiagent therapy. These groups may differ in functional status and previous treatment exposure. The exact distribution and outcomes for every clinically relevant subgroup should be evaluated from complete trial and label materials rather than inferred from the overall estimates. 615

Daraxonrasib also differs mechanistically from the targeted agents previously available to biomarker selected pancreatic cancer populations. RAS inhibition acts on a central driver pathway, and the approval language covers an overall metastatic population defined by treatment history or treatment suitability. This broad population makes testing strategy and real world tolerability relevant considerations as use expands. 26

The RASolute 302 efficacy results do not establish benefit as a universal first line alternative to established chemotherapy combinations, or in the postoperative setting. Additional studies and regulatory decisions would be needed to support those uses. 61

Safety and Treatment Selection

The daraxonrasib prescribing information includes warnings for dermatologic and soft tissue toxicity, stomatitis and oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo fetal toxicity. The FDA also identified rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, edema, reduced appetite, and hemorrhage among common adverse reactions. 6215

Treatment selection therefore requires assessment of a patient's prior systemic therapy, ability to receive an intensive regimen, underlying gastrointestinal and pulmonary risks, concomitant medicines, and willingness to manage effects associated with daily oral treatment. The FDA indication provides two eligibility paths, prior systemic treatment or inability to receive multiagent therapy. 615

Comparing toxicity rates across different clinical trials would be unreliable without aligned definitions, follow up, and populations. The respective prescribing information and current oncology treatment standards remain the appropriate sources for regimen specific safety decisions. 1158

The 2026 Regulatory Program

The approval followed a series of expedited development and access actions. Daraxonrasib received breakthrough therapy and orphan drug designations. The FDA assigned the program a Commissioner's National Priority Review Voucher in October 2025, and the sponsor sought expanded access while the drug remained investigational. 142

The publicly available Daraxonrasib development and approval pathway information can also be explored in Regulatory Designer, which maps disclosed clinical and regulatory milestones across the program.

On May 1, 2026, the FDA announced it had permitted an expanded access treatment protocol for previously treated metastatic PDAC. The agency reported that the sponsor submitted its request on April 28 and that the FDA issued its authorization on April 30. Expanded access permitted treatment under specified conditions before marketing approval and was separate from the clinical evidence establishing efficacy. 14

The August 26 approval used the FDA Oncology Center of Excellence's Project Orbis framework, with Health Canada collaborating and the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency observing. The agency also described use of the Real Time Oncology Review (RTOR) pilot and the Assessment Aid submission approach. 6

The FDA reported that it approved the application approximately 6.5 months before its goal date. This is a regulatory timing observation. It does not change the defined indication, or remove the need to review the drug's clinical evidence and safety profile in treatment decisions. 62

International Developments and Future Indications

The Project Orbis review shows the international dimension of the 2026 daraxonrasib assessment. The FDA stated that applications could still be under review at other participating regulatory agencies when the US approval was announced. Country specific authorization status and approved indications require confirmation in the respective regulator's current records. 617

Development in earlier lines of metastatic pancreatic cancer remains a separate regulatory question. Revolution Medicines publicly described an FDA breakthrough therapy designation in a first line development context, but breakthrough designation does not itself represent a marketing approval for a new indication. The evidence and status of any future label expansion would depend on its own submission and review. 186

As treatment moves beyond chemotherapy alone, clinical development will need to define how RAS inhibition interacts with first line regimens, biomarker selection, sequencing, and resistance. Specific trial outcomes, eventual dates of approval, and commercial adoption for those future settings are unspecified. 1618

Conclusion

Pancreatic cancer treatment in the United States has developed through successive advances in systemic chemotherapy, postoperative regimens, and precision treatments for molecularly defined populations. Those approaches created the context for a targeted agent that could serve a wider group of patients with metastatic disease.

The 2026 approval of daraxonrasib followed randomized evidence of longer overall and progression free survival and more frequent tumor responses than standard chemotherapy in previously treated metastatic pancreatic adenocarcinoma. Its approved role also encompasses patients who are unsuitable for multiagent systemic treatment.

The next decisions concern patient selection, side effect management, treatment sequencing, and evidence for earlier disease settings. As those questions develop, the existing FDA indications and their supporting trial populations remain essential to interpreting each therapy's place in care.